ANI Pharmaceuticals Inc (NASDAQ:ANIP)

During the Trading Day
60.39 +0.05 / +0.08%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
60.39 0.00 / 0.00%
 
Volume: 2.0K
Novo Nordisk's Onset 1 & Onset 2 Meet Primary Objectives - Analyst Blog
7:27pm / Zacks.com
ANI Pharmaceuticals (ANIP) In A Perilous Reversal
Mar 20 / TheStreet.com
Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog
4:55pm / Zacks.com
Lexicon-Ipsen Agreement Expanded to Include Canada - Analyst Blog
Mar 19 / Zacks.com
Lpath (LPTN) Crumbles on Failure of Kidney Cancer Drug Trial - Analyst Blog
Mar 25 / Zacks.com
Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog
Mar 18 / Zacks.com
Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog
Mar 24 / Zacks.com
Genomic Health Prostrate Cancer Test Grows but Hits Margins - Analyst Blog
Mar 18 / Zacks.com
Novo Nordisk's Saxenda Gets EU Approval for Obesity - Analyst Blog
Mar 24 / Zacks.com
Actelion's Uptravi Shows Long-term Benefit in GRIPHON - Analyst Blog
Mar 16 / Zacks.com
Myriad Poised on Portfolio Strength Despite Y/Y Downfall in Q2 - Analyst Blog
Mar 23 / Zacks.com
Epizyme (EPZM) Crumbles: Stock Falls by 9.6% - Tale of the Tape
Mar 16 / Zacks.com
Eli Lilly Partners with Innovent to Develop Oncology Drugs - Analyst Blog
Mar 23 / Zacks.com
Is Illumina (ILMN) Worth Adding to Your Portfolio Now? - Analyst Blog
Mar 13 / Zacks.com
Pfizer Reveals Detailed Xeljanz Data from Psoriasis Study - Analyst Blog
Mar 23 / Zacks.com
Affymetrix Hits 52-Week High on Stellar Q4, Positive Outlook - Analyst Blog
Mar 13 / Zacks.com
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Mar 20 / Zacks.com
Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog
Mar 13 / Zacks.com
Eli Lilly Collaborates with Korean Hanmi Pharmaceutical - Analyst Blog
Mar 20 / Zacks.com
Synta's Q4 Loss Narrows Y/Y, Focus on Lung Cancer Drug - Analyst Blog
Mar 13 / Zacks.com
Prothena's PRX002 Positive in Parkinson's Disease Study - Analyst Blog
Mar 20 / Zacks.com
TrovaGene (TROV) Posts Wider Q4 Loss on Higher Expenses - Analyst Blog
Mar 13 / Zacks.com
Insider Trading Alert - AEL, ANIP And CRM Traded By Insiders
Mar 20 / TheStreet.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account